IO Biotech Inc (IOBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IO Biotech Inc (IOBT) has a cash flow conversion efficiency ratio of -20.283x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.48 Million) by net assets ($911.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IOBT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
IO Biotech Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how IO Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
IO Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IO Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sadot Group Inc.
NASDAQ:SDOT
|
-0.042x |
|
Watkin Jones PLC
LSE:WJG
|
-0.050x |
|
Ivory Properties Group Bhd
KLSE:5175
|
0.629x |
|
Manz AG
F:M5Z
|
-0.114x |
|
Gyldendal A/S
CO:GYLD-B
|
0.262x |
|
Upland Resources Ltd
LSE:UPL
|
0.175x |
|
R.E.A. Holdings plc
LSE:RE
|
0.120x |
|
Ariana Resources plc
LSE:AAU
|
-0.024x |
Annual Cash Flow Conversion Efficiency for IO Biotech Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of IO Biotech Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market value of IO Biotech Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.02 Million | $-82.35 Million | -1.752x | -225.12% |
| 2023-12-31 | $133.16 Million | $-71.74 Million | -0.539x | -25.24% |
| 2022-12-31 | $138.85 Million | $-59.73 Million | -0.430x | -124.28% |
| 2021-12-31 | $211.92 Million | $-40.65 Million | -0.192x | +94.99% |
| 2020-12-31 | $2.60 Million | $-9.96 Million | -3.825x | -163.28% |
| 2019-12-31 | $-1.47 Million | $-8.89 Million | 6.044x | -- |
About IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more